Morgan Levine

Morgan Levine ran the Laboratory for Aging in Living Systems as a tenure-track assistant professor of pathology at Yale School of Medicine before joining Altos Labs, a well-funded longevity-focused biotechnology company, as a founding principal investigator at its San Diego Institute of Science in 2022 [3].

Levine's most cited scientific contribution is PhenoAge, an epigenetic biomarker of aging developed with Ake T. Lu, Steve Horvath (also profiled in this reference), and colleagues, published as "An epigenetic biomarker of aging for lifespan and healthspan" [1]. PhenoAge combines clinical chemistry biomarkers with DNA methylation data to generate a single score correlating with both current health status and future mortality risk; the paper reported that individuals in the fastest-aging 5% by this measure had 1.62 times the mortality hazard of an average-aging individual of the same chronological age [1]. This made PhenoAge one of the more clinically grounded of the second-generation epigenetic clocks, since it was trained directly on mortality and morbidity outcomes rather than chronological age alone.

Levine has also played a notable public role as a scientific fact-checker of biological-age claims circulating in longevity media. When entrepreneur Bryan Johnson publicized a DunedinPACE score suggesting he had reversed his biological aging rate by an equivalent of 31 years, Levine publicly corrected the interpretation, explaining that DunedinPACE measures the current pace of aging, meaning how fast someone is aging right now, not a stored, reversible "biological age debt" that can be paid down by 31 years in the way Johnson's framing implied [2]. This distinction matters mechanically: a low DunedinPACE score means someone is currently aging slowly, but it does not mean their cumulative biological age has been rolled back by that many years, and Levine's intervention is one of the more direct public corrections by a clock's own scientific community against an influencer's promotional use of a biomarker.

At Altos Labs, Levine's research shifted toward reprogramming-based approaches to rejuvenation, an area of the company's broader research portfolio alongside work by Steve Horvath and other Altos-affiliated scientists [3]. Altos Labs is a well-capitalized private company, reportedly with over $3 billion in funding from investors including Jeff Bezos, and its research findings are not always published with the same immediacy or openness as university lab output, a structural feature shared with Calico that makes independent, real-time evaluation of the company's internal progress more difficult than for academic labs [3].

Levine has received recognition within the academic aging-research community independent of her industry move, including the Vincent Cristofalo Rising Star Award in 2021 and the Nathan Shock New Investigator Award in 2020, both awarded before her transition to Altos Labs [3].

The plain takeaway: Levine's PhenoAge clock is a genuinely well-validated, peer-reviewed tool linking DNA methylation and clinical biomarkers to real mortality outcomes, and her public correction of the Bryan Johnson DunedinPACE claim is a useful, concrete example of a biomarker's own inventor community pushing back against promotional overreach; her current work inside a well-funded but comparatively closed private company means her most recent output is less independently checkable than her earlier, published Yale-era research.